High VEGFC mRNA expression of AML blasts is related to increased in vitro and in vivo drug resistance. The prognostic significance of VEGFC on long-term outcome and its associated gene expression profiles remain to be defined. We studied the effect of VEGFC on treatment outcome and investigated gene expression profiles associated with VEGFC using microarray data of 525 adult and 100 pediatric AML patients. High VEGFC expression appeared strongly associated with reduced complete remission rate (P = .004), reduced overall and event-free survival (OS and EFS) in adult AML (P = .002 and P <.001 respectively). Multivariable analysis established high VEGFC as prognostic indicator independent of cytogenetic risk, FLT3-ITD, NPM1, CEBPA, age and WBC (P = .038 for OS and P = .006 for EFS).
INTRODUCTION

Vascular endothelial growth factor-C (VEGFC) is a (lymph)angiogenic growth factor
and signals through kinase insert domain receptor (KDR, i.e. VEGF Receptor-2) and fms-related tyrosine kinase 4 receptor (FLT4, i.e. VEGF Receptor-3).
1;2 In general, by VEGF stimulation, VEGFRs become phosphorylated and transmit intracellular signals resulting in cell proliferation and survival. 3;4 Acute myeloid leukemic (AML) blasts express VEGFC and its receptors KDR and FLT4. 5 Exogenously added VEGFC promotes in vitro cell survival via activation of the FLT4 and KDR heterodimeric receptor, as shown in two AML cell lines and in five cases of primary AML. 6 Recently, we described that endogenous VEGFC mRNA expression levels of primary AML cells were related to increased in vitro resistance for six AML-related drugs. 7 In addition, a relation was demonstrated between high VEGFC mRNA and slow AML blast disappearance during induction treatment in vivo.
This was apparent from the higher blast counts in the bone marrow on day 15 after start of induction chemotherapy and a prolonged time to achieve complete remission. 7 Currently, insight into molecular mechanisms responsible for the unfavorable treatment response and possible relationships of VEGFC levels with other biological factors with prognostic significance is lacking. Furthermore, to date, the effect of VEGFC on long-term outcome has not been assessed in a large series of cases. We set out to study the effect of VEGFC on overall and event free survival (OS and EFS) both in pediatric as well as in adult AML and considered the impact of VEGFC in relation to other established cytogenetic and gene mutation prognostic markers. Finally, we investigated gene expression profiles associated with VEGFC mRNA expression by using Affymetrix HGU133Plus2.0 gene expression data of 525 adult and 100 pediatric AML cases.
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METHODS
Patients
Gene expression profiling (GEP) has been performed on 525 consecutive adult AML patients who have been treated according to sequential HOVON/SAKK AML-04, -04A, -29, -32, -42, -43 protocols (available at http://www.hovon.nl).
8-10 The adult and pediatric AML patients have been included in previous gene expression profiling studies. 11- 13 An independent second series of cell specimens from 100 newly diagnosed pediatric patients with AML -who have been treated according to subsequent Dutch Childhood Oncology Group (DCOG) AML DCOG-BFM-87, DCOG-92/94, DCOG-97 protocols (available at http://www.skion.nl), was used for validation of the data of the adult AML cohort. All adult as well as pediatric patients in this study were newly diagnosed with AML and established according to WHO criteria. All patients provided written informed consent in accordance with the Declaration of Helsinki, and the study was approved by all participating institutional review boards.
Cell specimens were collected at the time of diagnosis. All subjects provided written informed consent. 
Isolation and Quality Control of RNA, Gene Expression Profiling and Quality
Control
The samples for gene expression profiling were obtained and analyzed as described previously.
11;12 Detailed clinical, cytogenetic, and molecular information is available at the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo, accession number GSE6891 for adult AML patients and GSE22056 for pediatric AML patients).
Class comparison
Differentially expressed probes were identified for 262 AML samples with high 
Gene ontology analysis
To investigate the biological significance of the gene lists, we used GO (http://www.geneontology.org). After mapping each gene to the GO tree structure, the For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From number of genes was determined at or below any given node in the GO hierarchy and the amount of statistically enrichment (Fisher exact test and FDR adjustment) for each GO node relative to chance observation, using a previously developed procedure (GeneTrail).
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Statistical Analysis
Statistical analyses were performed with SPSS software, release 16.0. Actuarial probabilities of overall survival (OS) (with death due to any cause) as well as eventfree survival (EFS, with failure in case of no complete remission [CR1] or relapse or death) were estimated according to the Kaplan-Meier method. For quantitative parameters overall differences between the cohorts were evaluated using an F-test (or Student-t in case of two groups) for normally distributed variables or a KruskalWallis test (or Mann-Whitney-U test in case of two groups) for skewed distributed variables. For qualitative parameters, overall group differences were evaluated using a Chi-square test (or Fisher exact in 2x2 setting). Correlations were calculated with the Spearman rank correlation coefficient (rho). The association between VEGFC and OS and EFS was tested in univariate Cox models. Cox regression analysis was applied to determine the association of VEGFC expression and OS/EFS with adjustment for risk factors such as age, white blood cell count, cytogenetic risk group The proportional hazard assumption was checked using log-log survivor functions (parallel curves). In addition the presence of time-dependence indicating violation of Figure 1) . As the risks in first and second quartile were highly comparable and significantly different from third and fourth quartile, the median VEGFC level was chosen as the appropriate cut off point (hereafter referred to as high and low VEGFC). The latter cut off point corresponds with the threshold used in most previous studies on VEGFC mRNA/protein in various malignancies including AML.
7; [18] [19] [20] The complete remission rate was significantly lower among AML patients with high VEGFC as compared to those with low VEGFC (Table 1 Interestingly, CBF AMLs with high VEGFC showed a significantly reduced EFS (P = .017). In addition, patients harboring t(15;17) with high VEGFC expression showed no difference in OS (P = .582) but, interestingly, tend to show a reduced EFS (P = .084). Hereafter, the two largest specific cytogenetic subgroups of AML patients with For personal use only. on October 22, 2017. by guest www.bloodjournal.org From poor risk cytogenetics within our cohort (i.e. complex cytogenetics and -5(q)/-7(q) abnormalities) were compared for OS and EFS among patients with low versus high VEGFC. In patients with complex cytogenetics no effect of VEGFC on OS and EFS was evident (P = .676 and P = .851, respectively). Finally, patients with -5(q)/-7(q) cytogenetic abnormalities and high VEGFC tend to show a reduced OS (P = .067), but no effect was evident on EFS (P = .320). significantly affected OS and EFS (data not shown). When we subsequently, considered the latter variables in a multivariable analysis high VEGFC maintained its independent prognostic value for both OS as well as EFS: (HR: 1.29, 95% CI: 1.02-1.63, P = .038 for OS; HR: 1.38, 95% CI: 1.09-1.71, P = .006 for EFS) (details in Table 2 ).
Moreover, we evaluated AML patients with intermediate risk cytogenetics and considered VEGFC transcript level, FLT3-ITD and NPM1 gene mutation status separately. Patients with low VEGFC expression in the absence of a FLT3-ITD constituted a favorable subset of patients with a significantly improved OS and EFS compared to the other three groups combined (P = .026 for OS and P = .032 for EFS, Figure 2A and 2B). For patients with low VEGFC levels and absent FLT3-ITD, the estimated 5-year OS was 50% and the estimated EFS at 5 years was 40%. In contrast, the outcome of patients with both high VEGFC expression and FLT3-ITD were worse, as the 5-year OS and EFS rates were only 30% and 26%, respectively.
Of note, also within cytogenetically normal karyotype AML, patients with low VEGFC in the absence of a FLT3-ITD tend to have a better prognosis as compared with the other cytogenetically normal karyotype AML patients (P = .11 for OS and P = .04 for EFS, Supplementary Figure 3A and 3B respectively). Furthermore, patients with the combination of a high VEGFC level without a NPM1 mutation showed a nonsignificant trend as regards a reduced OS (P = .098, Supplementary Figure 4A) and a significantly reduced EFS compared to the other three groups combined (P = .012, Supplementary Figure 4B ).
Consistence of VEGFC as a prognostic factor in pediatric AML.
We wished to study the effect of VEGFC on outcome using an independent cohort of pediatric AML patients (Table 3 ) and defined patient subgroups on the basis of high and low VEGFC expression using the identical cut off point (i.e. median) as applied to the above adult series of AML. As in adult AML patients, the complete remission rate was significantly reduced in pediatric AML patients with high VEGFC (Table 3 , P = .048). Univariate analysis demonstrated that high VEGFC significantly affected OS in pediatric AML (HR: 1.81, 95% CI: 1.02-3.21, P = .044). For EFS a non significant trend was seen (HR: 1.57, 95% CI: 0.94-2.62, P =.087). Figure 3 shows the KaplanMeier plots for pediatric AML patients with high versus low VEGFC with regard to OS ( Figure 3A , P =.041) and EFS (P = .084, Figure 3B ). Thus, the VEGFC prognostic data in pediatric AML appear in general agreement with those in adult AML. Table   1 ). With regard to the differential expression of VEGFC itself, -as expected-the VEGFC gene was the highest ranked among the list of differentially expressed genes. Off note, when a more extreme cut off point for VEGFC was chosen (i.e. first vs fourth quartile) a highly comparable list of differentially expressed genes was found; 648/651 genes were similar between both methods.
Validation of VEGFC dependent differences in gene expression profiles.
In order to validate the list of differently expressed genes between AML samples with high vs. low VEGFC, two independent gene expression profiling cohorts were used;
i.e. the pediatric AML cohort described above (n = 100) and a publicly available adult AML gene expression profiling cohort (n = 180) 21 . The 459 "Up-with-VEGFC" genes and the 192 "Down-with-VEGFC" genes were individually validated as a continuous variable dependent on VEGFC. Hence, 345/459 (75%) "Up-with-VEGFC" as well as 59/192 (31%) "Down-with-VEGFC" genes could be confirmed (i.e. 'validation step 1'
in Figure 4A ) in the pediatric AML set. Subsequently, a third independent adult AML cohort described by Tomasson et al. (n=180) 21 was used for an additional validation (i.e. 'validation step 2' in Figure 4A ); 331/345 "Up-with-VEGFC" and 44/59 "Downwith-VEGFC" were found. In summary, of the differentially expressed genes upon VEGFC in the original dataset, 331 "Up-with-VEGFC" genes and 44 "Down-with-VEGFC" genes could be confirmed to be significantly differently expressed as a continuous variable depending on VEGFC in two independent AML cohorts ( Figure   4A ). The entire list of differentially expressed genes after two validation steps is presented in Supplementary Table 1 .
Biological processes enriched for "up and down with-VEGFC" genes.
Then biological processes (represented by GO-ontologies) enriched among AML samples with high vs. low VEGFC were analyzed. For this analysis, those genes which were significantly upregulated or downregulated after two validation steps, were used. This 331 ("Up-with-VEGFC") and 44 ("Down-with-VEGFC") differentially expressed genes consisted of 105 significantly "Up-with-VEGFC" and 56 significantly "Down-with-VEGFC" GO-ontologies (Supplementary Table 2 ). This analysis revealed for instance that genes involved in biological processes as proliferation, signal transduction (e.g. PAK3 and SOS2 which are both upstream activators of MEK1/ERK [22] [23] [24] [25] and PDK1 which is a direct activator of Akt/PKB 26;27 ), cell adhesion, vascular endothelial growth factor receptor activity (e.g. KDR, PDGFRA and NRP1), angiogenesis and wnt-protein binding were upregulated with increasing VEGFC.
Genes involved in biological processes as apoptosis (TIA1 and ANP32A), cellular metabolic process, cell communication and DNA dependent transcription were found to be downregulated with increasing VEGFC ( Figure 4B ).
DISCUSSION
In this study we show that adult as well as pediatric AML patients with a high VEGFC transcript level have an inferior disease outcome. To further improve the insight into the molecular mechanisms associated and possibly responsible for the differences in VEGFC related poor outcome in AML, we have analyzed expression profiles of 525 AML patients in relation to VEGFC. This analysis revealed, after validation in two independent AML cohorts of 100 children and 180 adults, distinct gene expression profiles in AML with high VEGFC versus low VEGFC expression.
VEGFC is predominantly known for its ability to promote the formation of new lymphatic vessels by inducing proliferation, migration and sprout formation of existing lymphatic endothelial cells (i.e. lymphangiogenesis). [28] [29] [30] [31] The spread of cancer cells from a primary tumor to the lymphatics and blood stream is now understood to be due to active recruitment of new lymphatics by tumor-derived VEGFC. ^ CEBPA mutation versus no CEBPA mutation. 
FIGURE 3
The 100 pediatric AML patients were split in a group with high VEGFC (i.e. above the median VEGFC level, n= 50) and a group with low VEGFC (i.e. below the median VEGFC level, n= 50) mRNA expression levels. Kaplan-Meier plots show the overall survival (A) and event-free survival (B) of pediatric AML patient subgroups with high versus low transcript levels of VEGFC. . The gene expression profiling cohort of 100 pediatric AML samples was used to validate the differentially expressed unique genes between samples with high vs low VEGFC (i.e. validation step 1). Hereafter an independent publicly available cohort of 180 adult AML samples was used (i.e. validation step 2). 20 After two validation steps 331 unique genes were found to be higher expressed in AML patients with high compared low VEGFC and 44 unique genes were found to be lower expressed in AML patients with high VEGFC compared to AML patients with low VEGFC.
(B) Biological processes (represented by Go-ontologies) enriched among the 331 ("Up-with-VEGFC") and 44 ("Down-with-VEGFC") differentially expressed unique genes revealed 105 significantly "Up-with-VEGFC" and 56 significantly "Down-with-VEGFC" Go-ontologies at the significance level of P <.05. 
